????? ?? ?? ? ??? ????????????? ????????????????? ???????????????????Unfit clients also have the alternative of venetoclax plus obinutuzumab (VO) as frontline therapy. This is predicated on the section III demo that compared VO with ClbO in elderly/unfit individuals.113 VO was excellent in terms of reaction price and progression-cost-free survival,